文献速递神经肿瘤

复发性高级别胶质瘤再照射的时机:一项单中心研究

Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.
PubMed 文献 · J Neurooncol · 2018-03-08

该单中心回顾性分析评估复发性高级别胶质瘤患者再照射时机对总生存期和无进展生存期的影响,纳入2007年1月至2015年3月间41例接受再照射的患者,再照射中位剂量30.6 Gy,中位分次剂量4 Gy。复发后总生存期为13个月,与再照射开始时间无显著相关性。

要点

  • 41例复发性高级别胶质瘤患者接受再照射,中位剂量30.6 Gy,中位分次剂量4 Gy。
  • 总生存期34个月,复发后总生存期13个月。
  • 复发后总生存期与再照射开始时间无显著相关性。

核心结论

  • 在本机构,再照射相比其他治疗选择实施较晚,但部分患者可能从更早的照射时间点获益。
  • 由于患者情况多样,精确的时间点仍应个体化评估。

研究设计与样本

  • 单中心回顾性分析,纳入2007年1月至2015年3月间41例复发性高级别胶质瘤患者。

主要发现

  • 再照射中位剂量30.6 Gy(范围20-40 Gy),中位分次剂量4 Gy(范围1.8-5 Gy)。
  • 总生存期为34个月,复发后总生存期为13个月。
  • 诊断复发后,患者中位1.2个月后接受额外手术切除,2.2个月后接受二线全身治疗,5.7个月后接受再照射(伴或不伴)。
  • 再照射开始后4.3个月评估肿瘤生长。
  • 第二次手术切除后总生存期为12.2个月,二线全身治疗开始后为11.7个月,再照射开始后为6.7个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is no standard treatment available for recurrent high-grade gliomas. This monoinstitutional retrospective analysis evaluates the differences in overall survival and progression-free survival in patients according to the timing of re-irradiation. Patients suffering from a glioblastoma who received re-irradiation for recurrence were evaluated retrospectively. The median overall survival (OS) and the median progression-free survival were compared with different treatment options and within various time periods. From January 2007 until March 2015, 41 patients suffering from recurrent high-grade gliomas received re-irradiation [median dose of 30.6 Gy (range 20-40 Gy) in median 4 Gy fractions (range 1.8-5 Gy)] in our institution after initial postoperative irradiation or combined radiochemotherapy. The OS in this population was 34 months, and the OS after recurrence (OS-R) was 13 months. After diagnosis of recurrence, patients underwent additional surgical resection after a median of 1.2 months, received a second-line systemic therapy after 2.2 months with or without re-irradiation after 5.7 months. Growth of the tumour was assessed 4.3 months after the start of re-irradiation. The OS after the second surgical resection was 12.2 months, 11.7 months after the start of the second-line systemic therapy, and 6.7 months after the start of re-irradiation. The OS-R was not significantly correlated with the start of re-irradiation after a diagnosis of recurrence or the time period after the previous surgery. At this institution, re-irradiation was performed later compared to other treatment options. However, select patients could benefit from irradiation at an earlier time point. A precise time point should still be evaluated on an individual basis due to the patient's diverse conditions.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zemlin A, Märtens B, Wiese B, et al. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study. J Neurooncol. 2018. PMID: 29520609. doi:10.1007/s11060-018-2824-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。